Subcutaneous advanced glycation end-products and lung function according to glucose abnormalities: The ILERVAS Project

Sánchez, Enric; Lecube, Albert; Betriu, Àngels; Hernández, Cristina; López‐Cano, Carolina; Gutiérrez-Carrasquilla, Liliana; Kerkeni, Mohsen; Yeramian, Andrée; Purroy, Francisco; Pamplona, Reinald; Farràs, Cristina; Fernàndez, Elvira; Barbé, Ferrán; Simó, Rafael; Ilervas,; Hernández, Marta; Rius, Ferrán; Polanco, Dinora; Torre, M. Sanchez De La; Torres, Gerard; Godoy, Pere; Portero‐Otín, Manuel; Jové, Mariona; Colàs-Compàs, L; Benabdelhak, Ikram; Miquel, Eva; Ortega, Marta; Valdivielso, José M.; Bermúdez, Marcelino; Martínez-Alonso, Montserrat

doi:10.1016/j.diabet.2018.04.002

Cited by 12 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, this relation also has been assessed in 1,924 Caucasian subjects without pulmonary disease according to the presence of glucose abnormalities (33). This cross-sectional study demonstrated that skin autofluorescence, a surrogate measurement of AGE, was related to a significant decrease in FVC and FEV1 values, which was aggravated among subjects with type 2 diabetes (33).…”

Section: Discussionmentioning

confidence: 94%

“…Previous data evaluated the potential association between advanced glycation end products (AGEs) and lung function in patients with chronic obstructive pulmonary disease, in which higher skin AGE deposition and plasma AGE concentration had been reported (32). Recently, this relation also has been assessed in 1,924 Caucasian subjects without pulmonary disease according to the presence of glucose abnormalities (33). This cross-sectional study demonstrated that skin autofluorescence, a surrogate measurement of AGE, was related to a significant decrease in FVC and FEV1 values, which was aggravated among subjects with type 2 diabetes (33).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Glucose Improvement on Spirometric Maneuvers in Patients With Type 2 Diabetes: The Sweet Breath Study

Gutiérrez-Carrasquilla

Sánchez

Barbé

et al. 2019

Diabetes Care

View full text Add to dashboard Cite

OBJECTIVEType 2 diabetes exerts a deleterious effect on lung function. However, it is unknown whether an improvement in glycemic control ameliorates pulmonary function. RESEARCH DESIGN AND METHODSProspective interventional study with 60 patients with type 2 diabetes and forced expiratory volume in 1 s (FEV1) £90% of predicted. Spirometric maneuvers were evaluated at baseline and after a 3-month period in which antidiabetic therapy was intensified. Those with an HbA 1c reduction of ‡0.5% were considered to be good responders (n = 35). RESULTSGood responders exhibited a significant improvement in spirometric values between baseline and the end of the study (forced vital capacity [FVC]: 78.5 6 12.6% vs. 83.3 6 14.7%, P = 0.029]; FEV1: 75.6 6 15.3% vs. 80.9 6 15.4%, P = 0.010; and peak expiratory flow [PEF]: 80.4 6 21.6% vs. 89.2 6 21.0%, P = 0.007). However, no changes were observed in the group of nonresponders when the same parameters were evaluated (P = 0.586, P = 0.987, and P = 0.413, respectively). Similarly, the initial percentage of patients with a nonobstructive ventilatory defect and with an abnormal FEV1 decreased significantly only among good responders. In addition, the absolute change in HbA 1c inversely correlated to increases in FEV1 (r = 20.370, P = 0.029) and PEF (r = 20.471, P = 0.004) in the responders group. Finally, stepwise multivariate regression analysis showed that the absolute change in HbA 1c independently predicted increased FEV1 (R 2 = 0.175) and PEF (R 2 = 0.323). In contrast, the known duration of type 2 diabetes, but not the amelioration of HbA 1c , was related to changes in forced expiratory flow between 25% and 75% of the FVC. CONCLUSIONSIn type 2 diabetes, spirometric measurements reflecting central airway obstruction and explosive muscle strength exhibit significant amelioration after a short improvement in glycemic control.The lungs are not conventionally included in the target list of organs that may be affected by type 2 diabetes. However, with its large vascularization and rich amount of collagen and elastin fibers, the lung parenchyma appears to be a potential target of chronic hyperglycemia (1-3). In fact, the same histological and physiologic disturbances that account for complications in other tissues may also be involved in the

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Effect of Glucose Improvement on Spirometric Maneuvers in Patients With Type 2 Diabetes: The Sweet Breath Study

Gutiérrez-Carrasquilla

Sánchez

Barbé

et al. 2019

Diabetes Care

View full text Add to dashboard Cite

show abstract

“…Similarly, results from the Study of Health in Pomerania also described a restrictive type of lung disease in 73 patients with type 1 diabetes, pointing to widespread collagen and elastin abnormalities as a main etiopathogenic mechanism [25]. In this way, skin autofluorescence, -a surrogate measurement of advanced glycation end products, has been related to a significant decrease in FVC and FEV1 values in subjects with prediabetes and type 2 diabetes [8].…”

Section: Discussionmentioning

confidence: 93%

“…Although some of them reported normal results [6], the impairment in pulmonary function was recurrently described in this population [7]. Some of the suggested mechanisms underlying lung involvement in type 2 diabetes, such as microangiopathic changes and non-enzymatic glycosylation of tissue proteins are also shared by type 1 diabetes and primarily associated with a restrictive pulmonary pattern [1,8,9]. The alarming increase in the prevalence of obesity among patients with type 1 diabetes also favors the negative impact of insulin resistance and low-grade inflammation on the growth and metabolism of bronchoalveolar epithelium and vascular smooth muscle [1,10].…”

Section: Introductionmentioning

confidence: 91%

Effect of Subcutaneous Insulin on Spirometric Maneuvers in Patients with Type 1 Diabetes: A Case-Control Study

Sánchez

Mizab

Sauret

et al. 2020

JCM

View full text Add to dashboard Cite

In order to compare spirometric maneuvers in adults according to the presence of type 1 diabetes, a case-control study including 75 patients with type 1 diabetes and 75 controls matched by sex, age, and body mass index were designed. In addition, 75 patients with type 1 diabetes were added to examine the potential the impact of subcutaneous insulin therapy on pulmonary function. Lung function measurements were assessed according to the global initiative for chronic obstructive lung disease guidelines. Basal insulin included long-acting insulin analogues and the delivered background insulin in patients with pump therapy. Bolus insulin included rapid-acting insulin analogues and the delivered insulin to cover postprandial hyperglycemias. Patients with type 1 diabetes showed lower spirometric values in comparison to the control group, together with a higher prevalence of forced expiratory volume in the first second (FEV1) <80% (10.7% vs. 2.7%, p = 0.044) and restrictive ventilatory pattern (10.7% vs. 0%, p = 0.006) The dose of basal insulin (U/kg/day) showed a negative correlation with forced vital capacity (FVC) (r = −0.205, p = 0.012) and FEV1 (r = −0.182, p = 0.026). The optimal cut-off value for identifying patients with a restrictive spirometric pattern was 0.5 U/kg/day of basal insulin. Additionally, basal insulin (U/kg/day) independently predicted the presence of both a restrictive spirometric pattern (OR = 77.1 (3.2 to 1816.6), p = 0.007) and an abnormal FEV1 (OR = 29.9 (1.5 to 562.8), p = 0.023). In patients with type 1 diabetes, higher basal insulin dosage seems to be related with an impairment of pulmonary function.

show abstract

“…The distribution of AGEs in wide range of organs is limited at a low basal level under normal conditions, while diabetes induces AGEs to accumulate in the lungs (32,33). Using the streptozotocin (STZ) induced diabetic mice, researchers detected an extensive accumulation of AGEs and pathological hyperplasia of extracellular matrix and interstitial connective tissue in the lung (34,35).…”

Section: Advanced Glycation End-products (Ages) and The Receptor For mentioning

confidence: 99%

Diabetes Mellitus Contributes to Idiopathic Pulmonary Fibrosis: A Review From Clinical Appearance to Possible Pathogenesis

Wang

Xiang

et al. 2020

Front. Public Health

View full text Add to dashboard Cite

Diabetes mellitus is a systematic metabolic disease characterized by persistent hyperglycemia, which complications often involve multiple organs and systems including vessels, kidneys, retinas, and nervous system. Idiopathic pulmonary fibrosis is a chronic, progressive, fibrotic disease with usual interstitial pneumonia patterns. With in-depth research, diabetic related lung injury has been confirmed, and the lung is also considered as one of the targeted organs of diabetes, which mainly manifests as the pulmonary fibrosis. Based on that, this review discusses the association between diabetes mellitus and idiopathic pulmonary fibrosis from clinical findings to possible mechanisms.

show abstract

Subcutaneous advanced glycation end-products and lung function according to glucose abnormalities: The ILERVAS Project

Abstract: Està subjecte a una llicència de Reconeixement-NoComercial-SenseObraDerivada 4.0 de Creative Commons

Cited by 12 publications

References 10 publications

Effect of Glucose Improvement on Spirometric Maneuvers in Patients With Type 2 Diabetes: The Sweet Breath Study

Effect of Glucose Improvement on Spirometric Maneuvers in Patients With Type 2 Diabetes: The Sweet Breath Study

Effect of Subcutaneous Insulin on Spirometric Maneuvers in Patients with Type 1 Diabetes: A Case-Control Study

Diabetes Mellitus Contributes to Idiopathic Pulmonary Fibrosis: A Review From Clinical Appearance to Possible Pathogenesis

Contact Info

Product

Resources

About